Sunitinib Induced Hypocalcemia and its Potential Role in the Treatment of Refractory Hypercalcemia
Journal Title: Open Access Journal of Endocrinology - Year 2017, Vol 1, Issue 1
Abstract
Background: Sunitinib, an oral multi-targeted tyrosine kinase inhibitor has been approved for the treatment of advanced pancreatic neuroendocrine neoplasms (pNENs). Aim: To describe a series of 12 patients with pNENs on sunitinib who developed hypocalcemia. Patients and Methods: Three patients developed hypocalcemia, grade 4, 1 and 2 respectively. Results: A 58-year-old man with a stage IV, grade 2, initially non-functioning pNEN (NFpNEN), developed disease progression with concomitant hypersecretion of parathyroid hormone related-peptide (PTHrP) and uncontrolled hypercalcemia. After one month of sunitinib treatment, grade 4 hypocalcemia (<6mg/dl) developed. Following treatment reinstitution at a lower dose, hypercalcemia became easily controlled. Another two patients with NFpNEN treated with sunitinib developed a grade 1 (8.2mg/dl) non-symptomatic and a grade 2 (7.2mg/dl) symptomatic hypocalcemia, both nine months after sunitinib was initiated. Conclusions: Sunitinib-induced hypocalcemia may be a common side-effect that could be of therapeutic significance in patients with pNEN and refractory PTHrP-related hypercalcemia.
Authors and Affiliations
Krystallenia I Alexandraki
Keywords
Related Articles
- EP ID EP448448
- DOI 10.23880/oaje-16000105
- Views 122
- Downloads 0
An Update on Etiopathogenesis and Management of Type 1 Diabetes Mellitus
The incidence of type 1 diabetes mellitus (T1DM) is increasing at a massive pace globally. It results possibly from a genetic susceptibility and exposure to an environmental trigger. What is important is to use guideline...
Lymphadenopathy in Autoimmune Thyroiditis: Paratracheal Lymph Nodes are Indeed Crucial
Cervical lymphadenopathy is common in patients with autoimmune thyroiditis and supposed to be pathognomic for the disease if found in the paratracheal compartment (Robbins level VI). The aim of this prospective study is...
Is it Useful to Perform FNAC in Thyroid Gland Diseases?
Background: Neck masses are usually benign, their clinical importance is primarily related to the need to exclude thyroid cancer Thyroid gland cancer accounts for 1% of all cancers and is responsible for 0.5% of death re...
Pseudohypoparathyroidism 1a – A New Case Report
Patients with Pseudohypoparathyroidism 1a (PHP-1a) have a typical phenotype, described for the first time by Albright, and therefore called Albright’s Hereditary Osteodistrophy (AHO). It is characterized by a round face,...
Unusual Association of Two Germline Rearrangements in CDC73/HRPT2 Gene: Complexity of Clinical Counseling in the Age of Genomic Medicine
Background: Primary hyperparathyroidism is a phenotype shared by several hereditary endocrine and non-endocrine cancer predisposition syndromes caused by heterozygous germline mutations deactivating tumor suppressor gene...